Rigvir Group made a strategic decision temporarily suspend the distribution of Rigvir in Latvia

Biotechnology company The Rigvir Group made a strategic decision on its own initiative, temporarily suspend the distribution of Rigvir medicines in Latvia, while maintaining the existing registration. Such decision is a logical and economically viable step that allows investment and administrative resources to be focused on the implementation of a coordinated research plan for the centralized registration in EU.

Contacts for Media Inquiries

Rigvir Group
Address: 9-7 Teatra street, LV–1050, Riga, Latvia
Phone: +371 67 716 132
E-mail: pr@rigvir.com